נפח מכירות החברה Ensysce Biosciences, Inc. (ENSC)

Ensysce Biosciences (ENSC) develops abuse-resistant opioid medications, relying on royalties from the licensing of its patents. The business's success depends on FDA approval and the effectiveness of its platform in preventing overdoses. Demand for safe pain management is driving the search for B2B partners. The company's sales performance dynamics demonstrate current operational liquidity, with the metric reaching 0.00, which is critical for accurate portfolio rebalancing.

This indicator measures the aggregate daily cash flow from product sales, allowing for an assessment of operational efficiency and market demand through the aggregation of daily receipts. By analyzing the sales volume dynamics of Ensysce Biosciences (ENSC), an investor can track the commercialization rates of the proprietary TAAP and MPAR platforms, where an upward trend confirms the successful implementation of opioid overdose prevention technologies into clinical practice.